We are aware of current issues with the ONS login. Please clear your device history/cache/cookies before attempting to log in. Thank you for your patience as we address this issue.

Oncology Drug Reference Sheet: Talazoparib

By: Kristine B. LeFebvre DNP, RN, NPD-BC, AOCN®

Published In: Voice

Publication Date: 2019-05-21

Description

Initially approved in 2018, talazoparib (Talzenna^®) capsules are indicated for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene HER2-negative locally advanced or metastatic breast cancer.

View Article @ voice.ons.org

ONS Drug Education

Short summaries of newly approved oncology-related therapies or drugs with new indications.

View All Drug Education

Oncology Drug Reference Sheet: Talazoparib

Description

ONS Drug Education

Related Topics